Before you continue… You really need to read this if you have diabetes. CLICK HERE now.(will open in new window)
Find The Lowest Price Right Here
NTC distribution of exhort releases announced today the assign of a Small Business Invention Research (SBIR) Phase II consent award from the Nation's Institute of General Medical Sciences. The award represents a continuing of a Stage I study, which initially demonstrated the viability of overcoming transgene silencing, formerly, a major barrier to successful gene cure. In addition to anti-silencing elements, the earlier work led to systematic advances to non-viral gene care, including : antibiotic-free vectors ; gene activity enhancers ; beating immune reactions to foreign DNA, a novel vaccine adjuvant, and DNA production enhancers, according to Clague Hodgson, NTC’s President.
“The work is reported in a few publications, now in press, from the R&D group1 controlled by Doctor. Jim Williams, NTC’s Chief Scientific Officer and the Principal Investigator on the project,” he announced. Through collaboration with investigators at Johns Hopkins University (JHU) and other institutions, the performance of non-viral gene cure and DNA vaccination using NTC’s vectors was demonstrated in mouse, rabbit, and pig models, as well as in the human ex vivo (cell treatment) mode.
NTC’s cooperators on the Phase II work include 2 JHU spinoff firms : Gene Facelift, LLC ; and Canton Biotechnologies, Inc. Gene Facelift (controlled by JHU graduate and businessman, Doctor. Aaron Tabor) is a cosmetic treatment for ageing skin, targeted at exciting skin cell growth and restoration. Tabor is also the inventor of a cutaneous delivery method and formulations, which are used together with NTC’s vectors to supply skin expansion factor genes. “The genetic cosmetic for contra-aging is just our first step,” expounded Dr . Tabor, “Our target is to use the same gene transfer technology to help kids struggling inherited blistering skin disorders ; incapacitated patients fighting pressure ulcers ; and, burn victims endeavoring to control infection and grow new skin. ” . Canton, under the leadership of JHU investigator and surgeon, Dr . John Harmon, is developing treatments for injure healing and diabetic ulcers, mixing proprietary JHU gene findings with electroporation delivery of the vectors.
Dr. Harmon’s laboratory has been working with DNA expression vectors to enhance wound healing for a decade. Harmon, “They have high transfection potency and astonishing safety features.
We are thrilled to be working with NTC to bring these vectors to the clinic.” . The grant is predicted to provide necessary information that the investigators can take to the FDA in support of impending controlled trials, according to Drs. Tabor and Harmon.